The tablets are indicated for smoking cessation and act as partial agonists of nicotinic acetylcholine receptors, helping reduce nicotine cravings while blocking its pleasurable effects. Shares of Zydus Lifesciences ended 1.5% in the green in the session on Thursday, August 7. The stock has fallen 2.8% in the year so far.
